Trials / Completed
CompletedNCT00710762
A Randomised Placebo-Controlled Phase II Study of Continuous Maintenance Treatment With BIBF 1120 Following Chemotherapy in Patients With Relapsed Ovarian Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 89 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to estimate the Progression Free Survival Rates (PFS) of patients with relapsed ovarian cancer after 9 months of continuous treatment with either BIBF 1120 or matching placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BIBF1120 | |
| DRUG | Placebo |
Timeline
- Start date
- 2006-03-01
- Primary completion
- 2008-09-01
- Completion
- 2014-03-01
- First posted
- 2008-07-04
- Last updated
- 2016-08-15
- Results posted
- 2014-12-04
Locations
11 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00710762. Inclusion in this directory is not an endorsement.